lidocaine hydrochloride · Powder Pharms · NDA 022114
Zingo
Earliest generic entry, as listed
28 Sep 2035
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 9370622. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9370622 | use U-1870 · sets the listed date | 28 Sep 2035 |
| US 9358338 | use U-1870 | 27 Apr 2035 |
| US 8540665 | use U-1438 | 22 Oct 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022114 · 001 · discontinued | system, intradermal | 0.5MG | 28 Sep 2035 |